Currently, there are 70.94M common shares owned by the public and among those 38.61M shares have been available to trade.
The company’s stock has a 5-day price change of 17.63% and 53.79% over the past three months. KNSA shares are trading 49.89% year to date (YTD), with the 12-month market performance up to 68.63% higher. It has a 12-month low price of $14.12 and touched a high of $22.65 over the same period. KNSA has an average intraday trading volume of 395.58K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 30.94%, 34.52%, and 42.78% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Kiniksa Pharmaceuticals International Plc. (NASDAQ: KNSA) shares accounts for 51.58% of the company’s 70.94M shares outstanding.
It has a market capitalization of $1.87B and a beta (3y monthly) value of 0.38. The stock’s trailing 12-month PE ratio is 242.75, while the earnings-per-share (ttm) stands at $0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.69% over the week and 4.58% over the month.
Earnings per share for the fiscal year are expected to decrease by -81.23%, and 2026.11% over the next financial year.
Looking at the support for the KNSA, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on May 03, 2024, with the firm’s price target at $34. BofA Securities coverage for the Kiniksa Pharmaceuticals International Plc. (KNSA) stock in a research note released on June 29, 2020 offered a Buy rating with a price target of $40. BofA/Merrill was of a view on April 01, 2020 that the stock is Buy, while Barclays gave the stock Overweight rating on March 11, 2019, issuing a price target of $26. Wedbush on their part issued Outperform rating on December 12, 2018.
